Lantus, Insulin Glargine News

War is brewing in the multibillion-dollar diabetes market. In particular, a major skirmish will soon be fought over which insulin products will emerge as victors in a changing landscape.

Ladies and gentlemen, thank you for standing by. Welcome to Biodel's Second Quarter Fiscal Year 2013 Financial Results Conference Call.

In order to facilitate an understanding of our operational performance, we comment on our business net income statement.

Sanofi 1Q Revenues: 8.1 billion 1Q Earnings: 1.6 billion Comments: Diabetes sales grew 20% to 1.5 billion driven by Lantus.

Zealand Pharma A/S announces that its licensing partner Sanofi today in its 2013 first quarter earnings report has provided an update on the status of the LantusA /LyxumiaA single combination development program.

Novo Nordisk A/S, the world's largest insulin maker, said it expects to overcome the rejection by U.S. regulators of the new Tresiba medicine within three to five years as the company conducts more tests.